Clinical Trials Directory

Trials / Unknown

UnknownNCT04307979

Acute High Fat Bulletproof Coffee vs Black Coffee on Metabolism, Inflammation and Cognitive Function in Healthy Adults

Impact of Bulletproof Coffee on Metabolism, Inflammation and Cognitive Function

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
University of British Columbia · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This study will determine whether acute ingestion of a high fat "Bulletproof Coffee" will lead to changes in plasma triglycerides, immune cell function, as well as cognitive function when compared to a black coffee.

Detailed description

In a randomized crossover design, participants will consume a single bulletproof coffee or a single black coffee separated by \~7 days. Each visit commences in the morning after an overnight fast of 10-12 hours, with no exercise the day prior, no coffee consumption the morning of testing, and completion of a food log for dietary duplication prior to visit 2. A fasting blood draw is obtained and cognitive function tests administered, along with questionnaires to assess gastrointestinal distress, arousal, and hunger/fullness before coffee consumption. Following this, one of the coffee beverages is consumed (randomized to each visit). Cognitive testing and questionnaires are completed at 60 minutes after finishing the coffee, another blood draw at 90 minutes, and then cognitive testing, questionnaires and a final blood draw 180 minutes after consuming the coffee. This procedure is repeated during their second experimental visit, in which they consume the remaining coffee based on their randomization.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTHigh-fat coffeeA high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.
DIETARY_SUPPLEMENTBlack coffeeA regular black coffee with no added caloric content.

Timeline

Start date
2020-01-01
Primary completion
2020-12-31
Completion
2020-12-31
First posted
2020-03-13
Last updated
2020-03-13

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT04307979. Inclusion in this directory is not an endorsement.